Current Pharmacotherapeutic Treatment Options in Parkinson's Disease

Disease-a-Month

Volumn 53, Issue 4, 2007, Pages 214-222

  Rezak, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BENZATROPINE MESILATE; BROMOCRIPTINE MESILATE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR AFFECTING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; NEURPRO; PERGOLIDE MESILATE; PLACEBO; PRAMIPEXOLE; PROCYCLIDINE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

BLURRED VISION; CLINICAL TRIAL; COGNITIVE DEFECT; COMPULSION; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; LEG EDEMA; LIVEDO RETICULARIS; MENTAL HEALTH; MOTOR DYSFUNCTION; NAUSEA; NEUROPATHOLOGY; NEUROPROTECTION; PARKINSON DISEASE; REVIEW; SIDE EFFECT; SLEEP DISORDER; SWEAT GLAND DISEASE; URINE RETENTION;

ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CHOLINERGIC ANTAGONISTS; DOPAMINE AGONISTS; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; NITRILES; PARKINSON DISEASE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 34250647459     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2007.05.002     Document Type: Review

References (31)

1. Jankovic J. Progression of Parkinson's disease: are we making progress in charting the course?. Arch Neurol 62 (2005) 351-352
2. Antonin A., and DSeNotaris R. And SPECT functional imaging in Parkinson's disease. Sleep Med 5 (2004) 201-206
3. Chadhuri K.R., Healy D.G., and Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5 (2006) 235-245
4. Kumar A., Calne S.M., Schulzer M., et al. Clustering of Parkinson's disease: shared cause or coincidence?. Arch Neurol 61 (2004) 1057-1060
5. Seidler A., Hellenbrand W., Robra B.P., et al. Possible environmental, occupational and other etiologic factors. I. Parkinson's disease: a case control study in Germany. Neurology 46 (1996) 1275-1284
6. Parkinson J. An Essay on the Shaking Palsy (1817), Sherwood, Nealy and Jones, London, England
7. Montastruc J.L., Rascol O., and Senard J.M. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 14 (1999) 725-730
8. Williams G.R., Kurland L.T., and Goldberg I.D. Morbidity and mortality with parkinsonism. J Neurosurg 24 (1966) 138-143
9. Cotzias G.C., Van W.M., and Schiffer L.M. Aromatic amino acids and the modification of parkinsonism. N Engl J Med 276 (1967) 374-379
10. Routtinen H.M., and Rinne U.K. Entacapone prolongs levodopa response in a one month double blind study in Parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 60 (1996) 36-40
11. Kurth M.C., Adler C.H., Hilaire M.S., et al. Tolcapone improves motor function and reduces levodopa requirements in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-placebo-controlled trial. Neurology 48 1 (1997) 81-87
12. Rajput A.H., Martin W., Saint-Hilaire M.H., et al. Tolcapone improves motor function in parkinsonian patients with the "wearing off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 49 (1997) 1066-1071
13. Colosimo C. The rise and fall of tolcapone. J Neurol 246 10 (1999) 880-882
14. Olanow W.C. Tolcapone and hepatotoxic effects. Arch Neurol 57 2 (2000) 263-267
15. Olanow C.W., and Calne D. Does selegeline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?. Neurology 42 suppl 4 (1992) 13
16. Parkinson Study Group. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 (1993) 176
17. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients not requiring levodopa. Ann Neurol 39 (1996) 29-36
18. Parkinson Study Group. Impact of deprenyl on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 39 (1996) 37-45
19. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321 (1998) 1364-1371
20. Olanow C.W., Mytilineou C., and Tatton W. Current status of selegeline as a neuroprotective agent in Parkinson's disease. Mov Disord 13 suppl 1 (1998) 55-58
21. Tatton W.G., Wadia J.S., Ju W.Y., et al. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl 48 (1996) 45-49
22. Stern M.B., Marek K.L., Freidman J., et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 19 (2004) 916-923
23. Rascol O., Brooks D., Melamed E., et al. Rasagaline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagaline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365 (2003) 947-954
24. Blanchet P.J., Konitsiotis S., and Chase T.N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13 5 (1998) 798-802
25. Verhagen Metman L., Del Dotto P., Blanchet P.J., et al. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids 14 1-3 (1998) 75-82
26. Perachon S., Schwartz J.C., and Sokoloff P. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D-1, D-2, and D-3 receptors. Eur J Pharmacol 366 (1999) 293-300
27. Hubble J.P., Koller W.C., Cutler N.R., et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 18 4 (1995) 338-347
28. Adler C.H., Sethi K.D., Hauser R.A., et al. Ropinirole for the early treatment of Parkinson's disease. Neurology 49 (1997) 393-399
29. Evans A.H., and Lees A.J. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 17 4 (2004) 393-398
30. Lieberman A. Dopamine agonists used as monotherapy in de novo Parkinson's disease patients: comparisons with selegeline. Neurology 42 suppl 4 (1992) 37-40
31. Lieberman A., Ranhosky A., and Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double blind, placebo controlled, parallel-group study. Neurology 49 (1997) 162-168